Topics covered: Orphan Drugs, High-Quality Biotech Stocks, FDA Approval Process, Emerging Pharmaceuticals, Biotechnology Fundamentals, Biotechnology and Pharmaceuticals, Biotechnology and Pharmaceutical Investing, Biotechnology and Pharmaceutical Companies Valuation
Companies covered: The Medicines Company (NASDAQ:MDCO), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Sanofi (NYSE:SNY), Pharmacyclics, Inc. (NASDAQ:PCYC), Merck & Company, Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), InterMune Inc., Gilead Sciences, Inc. (NASDAQ:GILD), Express Scripts Holding Company (NASDAQ:ESRX), Cubist Pharmaceuticals Inc., Baxter International Inc. (NYSE:BAX), Celgene Corporation (NASDAQ:CELG), ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Pfizer, Inc. (NYSE:PFE), Dynavax Technologies Corporation (NASDAQ:DVAX), Provectus Biopharmaceuticals, Inc. (AMEX:PVCT), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), XOMA Corporation (NASDAQ:XOMA), United Therapeutics Corporation (NASDAQ:UTHR), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Cardiome Pharma Corporation (NASDAQ:CRME)
